Famciclovir leads to failure of hematopoiesis, but may have the benefit of relieving myeloid expansion in MDS-like zebrafish.
Famciclovir leads to failure of hematopoiesis, but may have the benefit of relieving myeloid expansion in MDS-like zebrafish.
复制标题
DOI：
10.1016/j.taap.2020.115334
复制
发表时间：
2020-11
影响因子：
3.8
通讯作者：
Jing Li;Panpan Meng;R. Zhou;Yiyue Zhang;Qing Lin
中科院分区：
文献类型：
--
作者：
Jing Li;Panpan Meng;R. Zhou;Yiyue Zhang;Qing Lin
泛昔洛韦（FCV）是一种抗病毒药物，通常在骨髓移植后使用以预防病毒感染。然而，人们对它在造血中的作用知之甚少。在这里，通过利用斑马鱼模型，我们发现FCV暴露通过损害造血干细胞和祖细胞（HSPC）的增殖并诱导HSPC凋亡而导致造血衰竭。另一方面，FCV治疗可以有效缓解c-mybhyperMDS样鱼模型中的骨髓恶性肿瘤，并且不仅在胚胎阶段而且在成年斑马鱼中也发挥作用。这项研究表明，FCV 是一把双刃剑，具有很高的血液毒性，但适当的 FCV 治疗可能有利于 MDS 的治疗。
Famciclovir (FCV) is an antiviral drug that is often utilized after bone marrow transplantation to prevent viral infection. Yet, its role in hematopoiesis is poorly understood. Here, by utilizing a zebrafish model, we found that FCV exposure led to hematopoietic failure by impairing the proliferation of hematopoietic stem and progenitor cell (HSPC) and inducing HSPC apoptosis. On the other hand, FCV treatment could effectively relieve myeloid malignancies in thec-mybhyperMDS-like fish model, and played a role not only in the embryonic stage but also in adult zebrafish. This study reveals that FCV functions as a double-edged sword, with hematotoxicity at a high level, but that appropriate FCV treatment may be beneficial for the treatment of MDS.